

Online Table 7 – Fellow-Eye Visual Acuity by Treatment Group

Fellow Eye	18-week Primary Outcome				26-week Outcome*			
	Levodopa N=87		Placebo N=45		Levodopa N=86		Placebo N=45	
	N	%	N	%	N	%	N	%
Acuity Score								
20/12 (93-97 letters)	12	14%	4	9%	15	17%	7	16%
20/16 (88-92 letters)	44	51%	22	49%	34	40%	22	49%
20/20 (83-87 letters)	22	25%	16	36%	28	33%	13	29%
20/25 (78-82 letters)	8	9%	3	7%	9	10%	2	4%
20/32 (73-77 letters)	1	1%	0	0	0	0	1	2%
Mean (SD)	88.1 (4.4) ~20/16 ⁻²		88.0 (3.2) ~20/16 ⁻²		88.0 (4.5) ~20/16 ⁻²		88.2 (4.1) ~20/16 ⁻²	
Change from Baseline								
≥15 letters worse	0	0	0	0	1	1%	0	0
10-14 letters worse	0	0	0	0	0	0	0	0
5-9 letters worse	4	5%	3	7%	2	2%	4	9%
within 4 letters (±4)	68	78%	39	87%	74	86%	35	78%
5-9 letters better	15	17%	3	7%	7	8%	6	13%
10-14 letters better	0	0	0	0	2	2%	0	0
Mean (SD) letters	1.5 (3.0)		0.5 (3.1)		1.4 (3.6)		0.8 (3.3)	

SD = standard deviation

* All participants continued in the study regardless of whether they continued with study medication after the 18-week visit; 49 (56%) participants in the levodopa group and 24 (53%) participants in the placebo group continued study medication at the 18-week visit.